Anaplastic large cell lymphoma (ALCL) (ALK-1 negative)

Clinical trials for Anaplastic large cell lymphoma (ALCL) (ALK-1 negative) explained in plain language.

Never miss a new study

Get alerted when new Anaplastic large cell lymphoma (ALCL) (ALK-1 negative) trials appear

Sign up with your email to follow new studies for Anaplastic large cell lymphoma (ALCL) (ALK-1 negative), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

New chemo cocktail aims to treat rare lymphoma without heart damage

Disease control Not yet recruiting

This phase 2 trial tests a new chemotherapy combination called CAOP for elderly patients (65+) with untreated peripheral T-cell lymphoma, a rare blood cancer. The standard treatment often causes heart damage, but this regimen replaces the heart-toxic drug with a safer one. The st…

Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) (ALK-1 NEGATIVE)

Phase 2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control

Last updated Jun 27, 2026 12:08 UTC

Anaplastic large cell lymphoma (ALCL) (ALK-1 negative)

Get alerted when new Anaplastic large cell lymphoma (ALCL) (ALK-1 negative) trials appear

New chemo cocktail aims to treat rare lymphoma without heart damage